Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus CYPROHEPTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus CYPROHEPTADINE HYDROCHLORIDE.
CLARITIN-D 24 HOUR vs CYPROHEPTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
None Documented
None Documented
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine